Plexion

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: Plexion
Generic name: SULFACETAMIDE SODIUM, SULFUR
Manufacturer: Brava Pharmaceuticals, LLC
Product type: HUMAN PRESCRIPTION DRUG
SPL set ID: 8211c8ec-b501-4ac6-8185-b4b9758cdc1a
SPL ID: 463d23fc-cb49-0346-e063-6394a90a2df2
Version: 5
Effective date: 2025-12-18
Source export date: 2026-08-01
Source partition: 2
Source file: https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-08-01/5cbbf4af8f4e275ec50931155b30ffa7322568b9af8a1c936a47f6d6774862fd/drug-label-0002-of-0014.json.zip
Source manifest SHA-256: bdd1454d0606b622b70458a306b8a10d8a8787db06fd9f46e69c7f7a4524b630
Import run: 20260801T225920Z
Imported at: 2026-08-01 23:02:17

Harmonized routes table
Harmonized routes
TOPICAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 16 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
brand name		Plexion	openfda.brand_name
generic name		SULFACETAMIDE SODIUM, SULFUR	openfda.generic_name
manufacturer name		Brava Pharmaceuticals, LLC	openfda.manufacturer_name
ndc	package	57883-404-01	openfda.package_ndc
ndc	package	57883-404-60	openfda.package_ndc
ndc	package	57883-404-10	openfda.package_ndc
ndc	product	57883-404	openfda.product_ndc
ndc11	package	57883040410	derived:openfda.package_ndc
ndc11	package	57883040460	derived:openfda.package_ndc
ndc11	package	57883040401	derived:openfda.package_ndc
rxcui		1494827	openfda.rxcui
rxcui		1494170	openfda.rxcui
spl id		463d23fc-cb49-0346-e063-6394a90a2df2	id
spl set id		8211c8ec-b501-4ac6-8185-b4b9758cdc1a	set_id
unii		4NRT660KJQ	openfda.unii
unii		70FD1KFU70	openfda.unii

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNINGS: Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome. KEEP OUT OF THE REACH OF CHILDREN.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

ADVERSE REACTIONS: Reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported (see WARNINGS).